FDMT Stock Summary and Trading Ideas (4D Molecular Therapeutics | NASDAQ:FDMT)

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.

As of March 3, 2025, FDMT stock price declined to $4.46 with 187,012 million shares trading.

FDMT has a beta of 0.74, meaning it tends to be less sensitive to market movements. FDMT has a correlation of 0.01 to the broad based SPY ETF.

FDMT has a market cap of $206.18 million. This is considered a Small Cap stock.

Last quarter 4D Molecular Therapeutics reported $1,000 in Revenue and -$.90 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.07.

In the last 3 years, FDMT traded as high as $36.25 and as low as $4.20.

The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

FDMT has underperformed the market in the last year with a price return of -84.0% while the SPY ETF gained +18.5%. FDMT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.3% and -8.6%, respectively, while the SPY returned -0.6% and -2.7%, respectively.

FDMT support price is $4.22 and resistance is $4.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.